Studies have shown that ETNPPL is downregulated in malignancies, including colorectal cancer, gastric cancer and pancreatic cancer, and low expression of ETNPPL indicates poorer prognosis (Ding et al., 2016; Lucas et al., 2005). Here, ETNPPL is linked to colorectal cancer.